LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock
LFMDPDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 15, 2026 | $0.55 | 2026-01-05 | 2026-01-05 |
| October 15, 2025 | $0.55 | 2025-10-03 | 2025-10-03 |
| July 15, 2025 | $0.55 | 2025-07-03 | 2025-07-03 |
| April 15, 2025 | $0.55 | 2025-04-04 | 2025-04-04 |
| January 15, 2025 | $0.55 | 2025-01-03 | 2025-01-03 |
Dividends Summary
- Consistent Payer: LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock has rewarded shareholders with 17 dividend payments over the past 4 years.
- Total Returned Value: Investors who held LFMDP shares during this period received a total of $9.50 per share in dividend income.
- Latest Payout: The most recent dividend of $0.55/share was paid 8 days ago, on January 15, 2026.
- Yield & Schedule: LFMDP currently pays dividends quarterly with an annual yield of 9.87%.
- Dividend Growth: Since 2022, the dividend payout has decreased by 10.9%, from $0.62 to $0.55.
- Dividend Reliability: LFMDP has maintained or increased its dividend for 11 consecutive payments.
Company News
Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive produ...
LifeMD, Inc. announced a cash dividend of $0.5546875 per share for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on January 15, 2026. The announcement reflects the company's financial stability as a leading virtual primary care provider.
Novo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.
LifeMD announced lower cash-pay pricing for Wegovy and Ozempic medications at $199 per month, supporting patients paying out of pocket through its Weight Management Program in collaboration with Novo Nordisk.
The global non-sterile compounding pharmacy market is projected to grow from $5.97 billion in 2024 to $12.11 billion by 2034, driven by increasing demand for personalized medications and growing chronic diseases, with North America currently leading the market.
